



Confirmatory and quantitative analysis of fatty acid esters of hydroxy fatty acids in serum by solid phase extraction coupled to liquid chromatography tandem mass spectrometry



María Asunción López-Bascón^{a, b, c}, Mónica Calderón-Santiago^{a, b, c}, Feliciano Priego-Capote^{a, b, c, *}

^a Department of Analytical Chemistry, University of Córdoba, Córdoba, Spain


^b ceiA3 Agroalimentary Excellence Campus, University of Córdoba, Córdoba, Spain

^c Maimónides Institute of Biomedical Research (IMIBIC), Reina Sofía Hospital, University of Córdoba, Córdoba, Spain

HIGHLIGHTS

- Automated method to determine fatty acid esters of hydroxy fatty acids (FAHFAs).
- The method has been optimized to maximize sensitivity.
- The method was based on the on-line coupling between SPE and LC–MS/MS.
- The method was used to determine FAHFAs in a cohort of serum samples from volunteers.

GRAPHICAL ABSTRACT



ARTICLE INFO

Article history:

Received 17 May 2016

Received in revised form

15 September 2016

Accepted 17 September 2016

Available online 20 September 2016

Keywords:

Fatty acid esters of hydroxy fatty acids

Solid phase extraction

Serum

Liquid chromatography–mass spectrometry

Targeted analysis

ABSTRACT

A novel class of endogenous mammalian lipids endowed with antidiabetic and anti-inflammatory properties has been recently discovered. These are fatty acid esters of hydroxy fatty acids (FAHFAs) formed by condensation between a hydroxy fatty acid and a fatty acid. FAHFAs are present in human serum and tissues at low nanomolar concentrations. Therefore, high sensitivity and selectivity profiling analysis of these compounds in clinical samples is demanded. An automated qualitative and quantitative method based on on-line coupling between solid phase extraction and liquid chromatography–tandem mass spectrometry has been here developed for determination of FAHFAs in serum with the required sensitivity and selectivity. Matrix effects were evaluated by preparation of calibration models in serum and methanol. Recovery factors ranged between 73.8 and 100% in serum. The within-day variability ranged from 7.1 to 13.8%, and the between-days variability varied from 9.3 to 21.6%, which are quite acceptable values taking into account the low concentration levels at which the target analytes are found. The method has been applied to a cohort of human serum samples to estimate the concentrations profiles as a function of the glycaemic state and obesity. Statistical analysis revealed three FAHFAs with levels significantly different depending on the glycaemic state or the body mass index. This automated method could be implemented in high-throughput analysis with minimum user assistance.

© 2016 Elsevier B.V. All rights reserved.

* Corresponding author. Department of Analytical Chemistry, Annex C-3 Building, Campus of Rabanales, University of Córdoba, Córdoba, Spain.

E-mail address: q72prcaf@uco.es (F. Priego-Capote).

Abbreviations

ACE	automatic cartridge exchanger	PAHPA	palmitic acid-hydroxy-palmitic acid
BMI	body mass index	PAHSA	palmitic acid hydroxystearic acid
FAHFAs	fatty acid esters of hydroxy fatty acids	12-PAHSA	palmitic acid-12-hydroxy-stearic acid
FWHM	full width at half maximum	PO	palmitoleate
HPD	high-pressure syringe dispenser	POHPA	palmitoleic acid-hydroxy-palmitic acid
NL	Neutral Loss scan mode	POHPO	palmitoleic acid-hydroxy-palmitoleic acid
OA	oleate	12-POHSA	palmitoleic acid-12-hydroxy-stearic acid
OAHOA	oleic acid-hydroxy-oleic acid	SA	stearate
OAHSA	oleic acid-hydroxy-stearic acid	12-SAHSA	stearic acid-12-hydroxy-stearic acid
12-OAHSA	oleic acid-12-hydroxy-stearic acid	SAHOA	stearic acid-hydroxy-oleic acid
PAHOA	palmitic acid-hydroxy-oleic acid	SPE	solid-phase extraction
		SRM	selected reaction monitoring
		T2DM	type-2 diabetes mellitus

1. Introduction

In the last decades the prevalence of metabolic syndrome has increased in developed countries, mainly because of the rise of obesity [1]. Metabolic syndrome is a collection of risk factors associated to a higher risk for cardiac diseases, atherosclerosis, fatty liver disease and diabetes [1–3]. These diseases share risk factors, being the most important obesity and insulin resistance [1]. Nowadays, the most common disease in patients affected by metabolic syndrome is diabetes mellitus. In fact, type-2 diabetes mellitus (T2DM) is increasing worldwide at an epidemic rate, which is expected to reach 592 million afflicted individuals by 2035 as compared to 382 million reached in 2013 [1,4]. Obesity is one of the major risk factors for T2DM, since around 85% of subjects with T2DM are overweighted or obese [5]. Thus, the body mass index (BMI) is not only associated with chronic low-grade inflammation and increased oxidative stress, but also with insulin resistance and metabolic dysregulation [2,5].

Recently, a novel class of endogenous mammalian lipids endowed with antidiabetic and anti-inflammatory properties has been found [6–11]. Yore et al. in 2014 referred to this class of natural-occurring lipids as fatty acid-hydroxy fatty acids, abbreviated as FAHFAs [6,7]. The authors identified 16 FAHFAs by different combinations of the main long-chain fatty acids (palmitate, oleate, stearate or palmitoleate) conjugated to a hydroxylated version of one of the same set of fatty acids [7]. In that research, the FAHFAs content of blood, serum and adipose tissue taken from diabetic mice were compared to that from normal mice. Yore et al. reported that 6 of the 16 FAHFA species were upregulated by GLUT4 overexpression, the unique insulin-sensitive glucose transporter protein [7]. The most dramatically upregulated FAHFA in the overexpressing GLUT4 was palmitic acid hydroxystearic acid (PAHSA) [7]. In humans, the authors observed a strong association between PAHSA and insulin sensitivity, being PAHSA levels significantly lower in insulin-resistant individuals as compared to insulin-sensitive cases [6,7]. Additionally, the characterization of the most common FAHFAs found in normal tissues and serum [6] revealed that their levels were similar to other signalling lipids such as prostacyclins, prostaglandins, steroids and endocannabinoids. Research on FAHFAs has revealed multiple effects that improve glucose-insulin homeostasis, which suggests that restoring PAHSA levels in insulin-resistant individuals could have beneficial metabolic effects. In fact, Yore et al. showed that administration of these fatty acids to mice improved glucose uptake from blood, enhanced insulin secretion and relieved obesity-associated inflammation, suggesting that these naturally occurring fats could be used for diabetes therapy [6].

Despite the potential of these novel lipids for treatments of diabetes [6,9,10], further studies are needed both to establish their normal physiological levels in humans and to study their evolution after a specific treatment. However, the low nanomolar concentrations at which FAHFAs are present in serum make necessary the development of a method with enough sensitivity to determine FAHFAs, even in deficiency state. One option is to preconcentrate FAHFAs by the implementation of a solid-phase extraction (SPE) step, which has been used for quantitation of other compounds found at similar concentrations to FAHFAs such as prostaglandins [10], prostanoids [11,12], steroids [13,14], eicosanoids [15,16] or endocannabinoids [17,18]. In this research an automated qualitative and quantitative method based on on-line coupling of SPE and liquid chromatography–tandem mass spectrometry (LC–MS/MS) to maximize sensitivity has been developed for determination of FAHFAs. The method has been further applied to a cohort of individuals to evaluate the influence of the glycaemic state on FAHFA levels.

2. Materials and methods

2.1. Reagents

Palmitic acid-12-hydroxy-stearic acid (12-PAHSA), palmitoleic acid-12-hydroxy-stearic acid (12-POHSA), stearic acid-12-hydroxy-stearic acid (12-SAHSA) and oleic acid-12-hydroxy-stearic acid (12-OAHSA) were purchased from Cayman Chemicals (Ann Arbor, MI, USA) in solution. Concretely, standard solutions contained 1 mg of each FAHFA in 200 μ L of methyl acetate (5000 mg L⁻¹). Working solutions of each standard were prepared diluting the commercial standards at 500 μ g L⁻¹ in chromatographic grade methyl acetate from Scharlab (Barcelona, Spain).

Chromatographic grade methanol and ammonium hydroxide were purchased from Scharlab (Barcelona, Spain), while mass spectrometry grade ammonium acetate was purchased from Fluka (Spain). Deionized water from a Millipore Milli-Q water purification system was used for preparation of all aqueous solutions.

2.2. Instruments and apparatus

A microcentrifuge Sorvall Legend Micro 21R from Thermo Scientific (Waltham, MA, US) was used to separate the phases after protein precipitation. On-line sample preparation was carried out with an automated SPE workstation Prospekt-2 system from Spark Holland (Emmen, The Netherlands), which included an automatic cartridge exchanger (ACE) and a high-pressure syringe dispenser (HPD) for solvent delivery. The automated system was coupled to a

Download English Version:

<https://daneshyari.com/en/article/5131224>

Download Persian Version:

<https://daneshyari.com/article/5131224>

[Daneshyari.com](https://daneshyari.com)